Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:48:38 EDT Tue 07 May 2024
Enter Symbol
or Name
USA
CA



News for U:HZNP from 2023-05-08 to 2024-05-07 - 48 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2023-10-06 08:30U:HZNPNews ReleaseRule 17(e) Announcement - Horizon Therapeutics plc
2023-10-05 07:40U:HZNPNews ReleaseRule 17(d) Announcement ¢ € “ Horizon Therapeutics plc
2023-10-03 11:15U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-10-03 11:06U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-10-02 11:39U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-10-02 11:24U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-10-02 08:00U:HZNPNews ReleaseHorizon Therapeutics plc Announces New UPLIZNA ‚ ® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023
2023-09-29 11:45U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-09-29 10:00U:HZNPNews ReleaseNew Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA ‚ ® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes
2023-09-27 09:45U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-09-26 09:02U:HZNPNews ReleaseHorizon Therapeutics plc Named to U.S. News & World Report ¢ € ™s 2024 List of Best Companies to Work For in the Health Care Industry
2023-09-25 09:34U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-09-19 08:00U:HZNPNews ReleaseHorizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List
2023-09-13 08:00U:HZNPNews ReleaseQ32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
2023-09-13 08:00U:HZNPNews ReleaseQ32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
2023-09-06 16:15U:HZNPNews ReleaseHorizon Therapeutics plc ( ¢ € œHorizon ¢ € ) Rule 2.12 Announcement
2023-09-05 09:05U:HZNPNews ReleaseHorizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
2023-09-01 09:20U:HZNPNews ReleaseAmgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition
2023-09-01 09:20U:HZNPNews ReleaseAMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION
2023-08-23 08:00U:HZNPNews ReleaseHorizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups
2023-08-09 10:30U:HZNPNews ReleaseHorizon Therapeutics plc - Rule 2.12 Announcement
2023-08-08 07:00U:HZNPNews ReleaseHorizon Therapeutics plc Reports Second-Quarter 2023 Financial Results
2023-07-28 11:55U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-07-28 11:45U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-07-28 11:35U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-07-28 11:20U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-07-28 11:15U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-07-28 11:05U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-07-28 10:55U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-07-27 08:00U:HZNPNews ReleaseHorizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients
2023-07-17 08:00U:HZNPNews ReleaseHorizon Therapeutics plc to Release Second-Quarter 2023 Financial Results on Aug. 8, 2023
2023-07-06 08:00U:HZNPNews ReleaseLong-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA ‚ ® (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology
2023-06-30 12:30U:HZNPNews ReleaseNew Analysis of MRI Findings Shows UPLIZNA ‚ ® (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
2023-06-26 11:00U:HZNPNews ReleaseTEPEZZA ‚ ® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED)
2023-06-22 08:00U:HZNPNews ReleaseHorizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA ‚ ® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
2023-06-17 17:00U:HZNPNews ReleaseAdditional Data from Phase 4 TEPEZZA ‚ ® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration
2023-06-17 14:00U:HZNPNews ReleaseNew Data from TEPEZZA ‚ ® (teprotumumab-trbw) Clinical Trials and Real-World Analyses Shed Light on Link Between Thyroid Autoimmunity and Hearing Risks
2023-06-12 19:00U:HZNPNews ReleaseHorizon Therapeutics plc ( ¢ € œHorizon ¢ € ) Rule 2.12 Announcement
2023-06-12 08:00U:HZNPNews ReleaseUPLIZNA ‚ ® (inebilizumab-cdon) Pivotal Trial Publication Integrating MRI and Biomarker Evaluation Shows Accuracy and Uniformity of Attack Diagnoses for Neuromyelitis Optica Spectrum Disorder (NMOSD)
2023-06-05 08:00U:HZNPNews ReleaseHorizon Therapeutics plc Announces Data from the TEPEZZA ‚ ® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting
2023-06-02 11:50U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-06-02 11:40U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-06-02 11:30U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-06-01 08:00U:HZNPNews ReleaseBiomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA ‚ ® (inebilizumab-cdon)
2023-05-23 08:00U:HZNPNews ReleaseHorizon Therapeutics plc Announces Presentation of Data that Advances the Understanding of Rheumatic Diseases at the 2023 EULAR European Congress of Rheumatology
2023-05-16 11:46U:HZNPNews ReleaseHorizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by Amgen
2023-05-10 11:30U:HZNPNews ReleaseRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
2023-05-09 08:00U:HZNPNews ReleaseHorizon Therapeutics plc Ranks First in Overall Corporate Reputation by U.S. Patient Advocacy Groups